Among patients resistant to EGFR treatment, a subset tested positive for CCDC6::RET fusion, enabling successful therapy through combination with a RET inhibitor.39 In essence, while oncofusions represent potential therapeutic targets, their response to targeted inhibition can vary significantly, as demonstrated by the NCOA4/CCDC6::RET fusion emphasizing the critical need for continued research to understand their role in cancer. This evidence concerns the gene EGFR and cancer.